The KRAS mutation rate reaches the highest level in pancreatic ductal adenocarcinoma (PDAC), approximately 90%, and then in CRC patients with a mutation rate ranging from 30% to 50% 29. The gene discussed is KRAS; the disease is colorectal carcinoma.